First Trust Advisors LP Immunity Bio, Inc. Transaction History

First Trust Advisors LP

$127 Billion
Q3 2025

A detailed history of First Trust Advisors LP transactions in Immunity Bio, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 271,832 shares of IBRX stock, worth $565,410. This represents 0.0% of its overall portfolio holdings.

Number of Shares

271,832

Previous 548,506 50.44%

Holding current value

$565,410

Previous $1.45 Million 53.87%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$2.24 - $3.01 $619,749 - $832,788	-276,674 Reduced 50.44%	271,832 $668,000
Q2 2025 Aug 13, 2025	BUY	$1.89 - $3.44 $1.04 Million - $1.89 Million	548,506 New	548,506 $1.45 Million
Q4 2024 Feb 13, 2025	SELL	$2.56 - $6.17 $1.51 Million - $3.64 Million	-589,609 Reduced 77.91%	167,200 $428,000
Q3 2024 Nov 13, 2024	SELL	$3.32 - $6.7 $434,292 - $876,433	-130,811 Reduced 14.74%	756,809 $2.81 Million
Q2 2024 Aug 13, 2024	BUY	$4.82 - $9.15 $4.28 Million - $8.12 Million	887,620 New	887,620 $5.61 Million
Q1 2023 May 15, 2023	BUY	$1.35 - $4.78 $131,071 - $464,090	97,090 Added 166.23%	155,497 $283,000
Q4 2022 Feb 09, 2023	SELL	$4.35 - $6.77 $73,784 - $114,832	-16,962 Reduced 22.51%	58,407 $296,000
Q3 2022 Nov 14, 2022	BUY	$3.65 - $6.43 $54,374 - $95,787	14,897 Added 24.63%	75,369 $375,000
Q2 2022 Aug 12, 2022	BUY	$2.68 - $6.14 $162,064 - $371,298	60,472 New	60,472 $225,000
Q3 2021 Nov 15, 2021	SELL	$9.17 - $14.24 $2.29 Million - $3.56 Million	-250,096 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$13.41 - $22.4 $815,649 - $1.36 Million	-60,824 Reduced 19.56%	250,096 $3.57 Million
Q1 2021 May 14, 2021	BUY	$12.83 - $42.25 $3.99 Million - $13.1 Million	310,920 New	310,920 $7.38 Million

Others Institutions Holding IBRX

# of Institutions

297

Shares Held

137M

Call Options Held

2.59M

Put Options Held

3.35M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $833M
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.

Account

First Trust Advisors LP Immunity Bio, Inc. Transaction History